Dr Simon Pacey

Cambridge University Hospitals NHS Foundation Trust
University of Cambridge

University departments
Department of Oncology

Position: Academic Consultant in Medical Oncology
Personal home page: http://www.oncology.cam.ac.uk/
Email:   simonpacey@medschl.cam.ac.uk

PubMed journal articles - click here

Dr Simon Pacey is pleased to consider applications from prospective PhD students.

Research description

As a Medical Oncologist trained in early drug development, my research interests are: Early phase clinical trials (phase I/II) and Urological malignancy (prostate cancers). My projects are centered around the transition of new drugs into humans and exploring and proposing new treatments paradigms for men with early/ localised prostate cancer. My clinical trial portfolio includes a significant proportion of investigator-led, locally sponsored clinical trials.

Examples of open clinical trials include:

Do Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving Durvalumab. Chief Investigator, investgiator-led. NCT03653052

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions) (STARTRK-2). UK Chief Investigator. NCT02568267

Cambridge Liquid Biopsy and Tumour Profiling Study for Patients on Experimental Therapeutics Trials. Co-PI, investigator led. NCT02994511

A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer. NCT04148937

Study to Evaluate CCS1477 in Advanced Tumours. NCT03568656

Abiraterone Acetate in Combination With Tildrakizumab. NCT04458311

Recent projects include:
- Chief Investigator Cambridge Neoadjuvant Carcinoma of the Prostate (CANCAP) studies: Clinical studies of investigational drugs prior to radical prostatectomy,  clinicatrials.gov identifiers NCT02064608 (AZD2014), see GU ASCO 2017 and NCT02324998 (Olaparib)
- Therapeutics in Active Surveillance, TAPS study of apalutamide NCT03365297
- Pre-clinical studies to investigate effect of mTOR inhibition in early, hormone sensitive prostate cancer

Research Programme or Virtual Institute
Urological Malignancies Virtual Institute
Secondary Programme
Fundamental Biology of Cancer
Strategic Resources
Cambridge Experimental Cancer Medicine Centre (ECMC)
NIHR Cambridge Biomedical Research Centre (BRC)
Methods and technologies
Clinical practice
Clinical trials
Tumour type interests
Recent publications:
 Retrieving latest data from feed...

Symplectic Elements feed provided by Research Information, University of Cambridge

Key publications

Tumor necrosis factor receptor-2 signaling pathways promote survival of cancer tem-like CD133+ cells in clear cell renal carcinoma. Bradley JR, Wang J, Pacey S, Warren AY, Pober JS, Al-Lamki RS. FASEB Bioadv. 2020 Jan 3;2(2):126-144. PMID: 32123862

A Phase I Study of Pegylated Arginine Deiminase (Pegargiminase), Cisplatin, and Pemetrexed in Argininosuccinate Synthetase 1-Deficient Recurrent High-grade Glioma. Hall PE, Lewis R, Syed N, Shaffer R, Evanson J, Ellis S, Williams M, Feng X, Johnston A, Thomson JA, Harris FP, Jena R, Matys T, Jefferies S, Smith K, Wu BW, Bomalaski JS, Crook T, O'Neill K, Paraskevopoulos D, Khadeir RS, Sheaff M, Pacey S, Plowman PN, Szlosarek PW. Clin Cancer Res. 2019 May 1;25(9):2708-2716. PMID: 30796035

Using prognosis to guide early detection and treatment selection in non-metastatic prostate cancer. Gnanapragasam VJ, Barrett T, Massie C, Pacey S, Warren A. BJU Int. 2019 Apr;123(4):562-563. doi: 10.1111/bju.14637. PMID: 30499634

Enhanced detection of circulating tumor DNA by fragment size analysis. Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, Mair R, Goranova T, Marass F, Heider K, Wan JCM, Supernat A, Hudecova I, Gounaris I, Ros S, Jimenez-Linan M, Garcia-Corbacho J, Patel K, Østrup O, Murphy S, Eldridge MD, Gale D, Stewart GD, Burge J, Cooper WN, van der Heijden MS, Massie CE, Watts C, Corrie P, Pacey S, Brindle KM, Baird RD, Mau-Sørensen M, Parkinson CA, Smith CG, Brenton JD, Rosenfeld N. Sci Transl Med. 2018 Nov 7;10(466). PMID: 30404863

A novel Atg5-shRNA mouse model enables temporal control of Autophagy in vivo. Cassidy LD, Young AR, Pérez-Mancera PA, Nimmervoll B, Jaulim A, Chen HC, McIntyre DJO, Brais R, Ricketts T, Pacey S, De La Roche M, Gilbertson RJ, Rubinsztein DC, Narita M. Autophagy. 2018;14(7):1256-1266. PMID: 29999454

Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1-Deficient Thoracic Cancers. Beddowes E, Spicer J, Chan PY, Khadeir R, Corbacho JG, Repana D, Steele JP, Schmid P, Szyszko T, Cook G, Diaz M, Feng X, Johnston A, Thomson J, Sheaff M, Wu BW, Bomalaski J, Pacey S, Szlosarek PW. J Clin Oncol. 2017 Jun 1;35(16):1778-1785. PMID: 28388291

Liquid biopsies come of age: towards implementation of circulating tumour DNA.
Wan JCM, Massie C, Garcia-Corbacho J, Mouliere F, Brenton JD, Caldas C, Pacey S, Baird R, Rosenfeld N. Nat Rev Cancer. 2017 Apr;17(4):223-238. PMID: 28233803

The role of chemotherapy and new targeted agents in the management of primary prostate cancer. Kumar SS, Pacey S. J Clin Urol. 2016 Dec;9(2 Suppl):30-37. PMID: 28344814